CES 2023: OMRON Healthcare to Unveil New Efforts to Realize Vision of “Going for Zero” — Zero Heart Attacks and Zero Strokes

– “Viso,” New UK Remote Patient Monitoring Service, to Be Launching in Early 2023 – OMRON Healthcare Co., Ltd. (hereinafter the Company) is unveiling a new UK remote patient-monitoring service to realize its “Going for Zero” vision to eliminate heart attack and stroke at the world’s largest Consumer Electronic Show (CES 2023). The Company is […]

thaipr.net

6 ม.ค. 66

Promising Singaporean Medtech Firm Osteopore Achieves Record Revenue, Enters New Markets and Operates in All Major Continents in 2022

Singapore-based Medtech Firm Osteopore announces their record revenue of $460,684 for Q3 CY22, an increase of 6.6% over the preceding quarter. As an extension of the same financial year, Osteopore has likewise broadened their regional operations to span Colombia, South Africa, Spain, and UAE to serve more demographics across the globe. Osteopore was founded in 2003 by a small team of inventors […]

thaipr.net

28 ธ.ค. 65

Hetero’s ‘Nirmacom’ is world’s first generic version of COVID-19 oral drug ‘PAXLOVID’ to receive WHO Prequalification

Hetero, India’s leading pharmaceutical company with the widest global reach, today announced the receipt of World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate nirmatrelvir. This is the first prequalification for a generic version of Pfizer’s COVID-19 oral antiviral drug ‘PAXLOVID’, which the WHO […]

thaipr.net

27 ธ.ค. 65

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached Complete Response at 1-month post treatment. The trial is taking place […]

thaipr.net

21 ธ.ค. 65

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. This agreement covers the…

thaipr.net

21 ธ.ค. 65

‘NCDs in Focus Act Now’ Summit organized by Viatris

The summit aimed to build synergies between healthcare professions and policy makers, addressing the challenges in the management of NCDs in Southeast Asia Viatris Inc. (NASDAQ: VTRS): The ‘NCDs in Focus Act Now’ Summit was recently organised by global healthcare company, Viatris, in collaboration with the Thai Hypertension Society and the Thai NCD Alliance. The objective of the […]

thaipr.net

19 ธ.ค. 65
1 48 49 50 51 52 128